Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

Effect of marital status and race on survival of patients with well differentiated neuroendocrine tumors (NETs). Clinicopathological factors related to survival in gastroenteropancreatic ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors at an advisory committee meeting. Exelixis disclosed the ...

Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...

With positive results from a phase III study, ITM Isotope Technologies Munich SE said it has reached a landmark. The clinical trial of ITM-11, a synthetic, targeted radiotherapeutic agent for treating ...

Median PFS improved from 11.5 months with single-agent everolimus to 29.7 months with the addition of lanreotide. Objective responses occurred about three times as often with the ...

and neuroendocrine tumors (NETs), which are neoplasms that arise from cells of the endocrine and nervous systems. Cushing syndrome (CS) is defined by signs and symptoms caused by hypercortisolism.

Jan. 28, 2025 — A new study shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study suggests that doctors may need to ...

Jan. 28, 2025 — A new study shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study suggests that doctors may need to ...